Santhera Pharmaceuticals, a Swiss specialty drug company focused on rare neuromuscular diseases, has appointed Stifel Nicolaus Europe Limited as its corporate finance advisor. The engagement will focus on capital‑market activities and outreach to international institutional investors, broadening Santhera’s access to global capital sources.
Santhera’s financial position underscores the strategic importance of the new advisory relationship. In the first half of 2025 the company generated CHF 24 million in revenue, a 70 % increase from CHF 14.8 million in the same period of 2024, while reporting a net loss of CHF 38.8 million. Cash and cash equivalents stood at CHF 18.4 million as of June 30 2025, giving the company a runway that extends to the middle of 2026. AGAMREE® (vamorolone), the company’s flagship product, has received regulatory approvals in the U.S., EU, UK, China, Hong Kong, and Canada, and sales of the drug exceeded USD 100 million on a four‑consecutive‑quarter basis.
Stifel’s own recent performance highlights the strength of the partnership. The investment‑banking arm of Stifel Financial Corp. reported net revenues of $5.53 billion for 2025 and a net income of $255 million in the fourth quarter of 2025, underscoring the firm’s capacity to support high‑growth specialty‑pharma clients. The new client adds a high‑growth segment to Stifel’s advisory portfolio and reinforces its presence in the European pharmaceutical market.
The advisory role will encompass a range of capital‑market activities, including debt and equity financing, and will involve targeted outreach to institutional investors worldwide. Stifel will work alongside Octavian AG, which will continue to provide advisory services, with responsibilities divided to maximize investor coverage and leverage Stifel’s established relationships in the specialty‑pharma space. The partnership is intended to support Santhera’s ongoing commercialization of AGAMREE® and to position the company for future capital raises that could fund pipeline development and operational expansion.
The appointment signals Santhera’s proactive approach to strengthening its financial position and achieving cash‑flow break‑even by mid‑2026. By engaging Stifel, the company gains access to a broader investor base and the expertise required to navigate the specialty‑pharma capital‑market landscape. For Stifel, the deal expands its footprint in a high‑growth niche and demonstrates its ability to deliver tailored financing solutions to companies with complex regulatory and commercial profiles.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.